New Insight with Dr. Veeral Sheth

Don’t Miss a Beat

Crisis Point

Professor of nursing at University of Alabama Huntsville and nurse practitioner and transplant coordinator at Vanderbilt University.

Examining APP-Led Endobronchial Valve Therapy for COPD, with Haley Hoy, PhD, CRNP

Advanced practice practitioners (APPs) can have a valuable role in pulmonary care and specifically chronic obstructive pulmonary disease (COPD). One analysis looking into an APP-led care model for patients with COPD was presented at the 2nd Annual Association of Pulmonary Advanced Practice Providers (APAPP) conference, held June 26-28, 2025, in Nashville, Tennessee, by Haley Hoy, PhD, CRNP, professor of nursing at University of Alabama Huntsville and nurse practitioner and transplant coordinator at Vanderbilt University.

spoke with Hoy to learn more about her experience with APP-led care models and how these, in combination with patient-centered strategies, can significantly change the trajectory of treatment, particularly for patients being evaluated for endobronchial valve therapy in rural settings. She reflected on her experience coordinating care in a rural outreach clinic, where transportation barriers and limited specialty access often delay interventions, and emphasized that in some settings, APPs can accelerate diagnosis, streamline referrals, and advocate for appropriate treatment in complex pulmonary cases.

“I think both in outreach, patient education and patient advocacy are places where a PPS make a big difference,” Hoy said.

She also discussed findings from the analysis, presented in a poster at last month’s meeting, that examined how different coordinator roles shape the diagnostic process, care timelines, and team-based efficiency.

“It was interesting to be a little more granular in our approach as to, when it comes to an endobronchial valve clinic, how you can better utilize people working at their scope of practice,” she said.

Hoy H, Priebe R. Bronchoscopic Lung Volume Reduction with Endobronchial Valves: Advancing COPD Care Through APP-Led Coordination. Presented at: APAPP 2025, June 26-28, 2025; Nashville, Tennessee.

Videos

Explore how advanced practice practitioners enhance COPD care through innovative models, improving patient outcomes and addressing rural healthcare challenges.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

A new review has been published highlighting different studies’ findings on the use of various 

 among breastfeeding mothers, with a detailed discussion provided on each medication’s transference to breast milk, blood serum levels in infants, potential adverse events among neonates, and other clinical considerations.

These data were all authored by a team of investigators, led by Carli D. Needle, an MD candidate at The Ronald O. Perelman Department of Dermatology at New York University’s Grossman School of Medicine. Needle et al noted that alopecia areata, androgenetic alopecia (AGA), and cicatricial alopecia can each lead to negative physical symptoms and notable psychological distress among patients and women in particular.

“Given the limited research in this area and the importance of avoiding interruptions in alopecia treatment, this review aims to help guide clinicians in choosing safe and appropriate hair loss therapies for women during lactation,” Needle and coauthors wrote.

The trial investigators carried out their literature searches using the Scopus, PubMed, and Web of Science databases. Searches were done only in English. Existing safety databases such as the Drugs and Lactation Database (LactMed) and the United States Food and Drug Administration (FDA) Drug Database were also used by the team, and any primary literature cited by these databases was further examined when accessible. Terms included the medication names and classes assessed by this review, as well as “lactation” and “breastfeeding.” Searches were done from November 2024 - December 2024.

The investigators noted the increasing systemic and topical medication use in alopecia treatment. The hair regrowth medication minoxidil is generally classified as low-risk during lactation, with oral being documented in breastfeeding mothers without complications. Nevertheless, because of possible transmission through skin contact or milk, cautious utilization of minoxidil is still being advised, especially in premature infants or neonates.

Needle and coauthors highlighted that Janus kinase inhibitors (JAKi), which reduce inflammation by targeting T-cell signaling pathways, are among some of the most effective. Approved JAKis for alopecia areata include baricitinib, deuruxolitinib, and ritlecitinib. As a result of their small molecular size, JAK inhibitors can pass into breast milk, contributing to concerns about infant exposure.

Tofacitinib appears in human breast milk within hours of ingestion, leading to current guidelines to avoid breastfeeding while implementing it. For other JAKis, such as baricitinib and ritlecitinib, lactation safety data are limited, though pharmacokinetic modeling suggests drug levels fall below clinical significance within several half-lives. Given uncertainty, those using such drugs are typically advised to pause breastfeeding during active JAKi use.

Needle and colleagues pointed to a variety of other research, noting different recommendations based on the drugs available for alopecia. Methotrexate, for example, only enters breast milk in small amounts but its active metabolite can linger in neonatal tissues as a result of immature infant kidney function. Even low levels of exposure is linked to potential developmental toxicity, so methotrexate is contraindicated during breastfeeding.

Other data highlighted by the investigative team included diphencyprone (DPCP), a topical option often used in alopecia areata that also acts as a contact allergen, triggering localized immune responses to encourage hair regrowth. Despite noted minimal systemic absorbtion, rare reports of DPCP entering circulation do exist. The lack of robust data, the team suggest, suggests a need for caution until further research is available.

The investigators further highlighted azathioprine that is now applied in autoimmune dermatologic conditions, noting that most experts recommend waiting a few hours after dosing before breastfeeding to allow peak concentrations of the medication to subside. They further pointed to cyclosporine, adding that variable transmission into breast milk has been observed with the drug and largely depends on the formulation. Generally, cyclosporine is considered compatible with breastfeeding, though infants should be monitored for potential adverse effects.

The Excimer laser, a narrow-band ultraviolet B (NB-UVB) therapy used to manage autoimmune scalp conditions, was noted as effective and generally safe, though folate supplementation was highlighted as necessary for consideration in postpartum mothers given this treatment. Needle et al pointed to data suggesting poor absorbtion of topical vitamin D analogues like calcipotriene during lactation, but noted that oral vitamin D is safe up to 10,000 IU daily, and supplementation in the mother may benefit infants given low levels of breast milk vitamin D.

For androgenetic alopecia, spironolactone is an anti-androgen agent that appears in breast milk only in trace amounts and has not been linked to infant harm. In a similar vein, topical clascoterone was shown to have lower systemic absorption, though safety during lactation was noted as not well established. Other findings in the review suggest that progestin-only pills, particularly drospirenone, have no adverse effects among breastfed infants when introduced after 6 weeks postpartum.

Other topical treatments like ketoconazole 2% shampoo, often implemented in scalp inflammation, were noted as safe resulting from their negligible levels of systemic absorption. Low-level laser therapy (LLLT), frequently utilized in hair regrowth procedures, is also regarded as safe during lactation due to its noninvasive nature and lack of drug interaction. Platelet-rich plasma (PRP) was shown by the investigators' review to pose minimal risk for breastfed infants. Some natural or plant-based therapies, including saw palmetto and rosemary oil, had less data and were not recommended.

For scarring (cicatricial) alopecias, topical tacrolimus is considered to be safe due to limited systemic absorption, though available data suggests direct contact with the infant skin should be avoided. Hydroxychloroquine was noted by Needle et al as being excreted in small amounts into breast milk, though it has not been linked to harms among infants. The antibiotic doxycycline was shown by the team to generally be safe for short-term use during lactation.

They highlighted that mycophenolate mofetil is not considered safe during breastfeeding given the high transfer into milk and risks linked to its use such as infections or developmental delays. Pioglitazone, a metabolic agent, is also shown to have produced harmful effects in animal studies and should be avoided. The investigators did, however, highlight the safety of low-dose naltrexone, sometimes used off-label for inflammatory conditions, which has shown minimal transmission into milk.

Clindamycin and rifampicin, both antibiotics used for inflammatory scalp conditions, are compatible with breastfeeding. However, Needle and coauthors did note that infants should be monitored for any GI symptoms. Retinoids like isotretinoin and acitretin were noted as being contraindicated given their high risk of toxicity and birth defects. In contrast, topical retinoids were shown to be likely safe.

The review also highlighted tumor necrosis factor (TNF) inhibitors such as adalimumab, primarily utilized in resistant inflammatory alopecias, which data suggest do appear in breast milk at very low levels. The protein molecules are broken down in an infant’s gut and are not absorbed systemically, making them compatible with breastfeeding.

“Although breastfeeding confers well-established health benefits, some individuals may choose to prioritize treatment for alopecia over continued breastfeeding, especially when effective therapies are not fully validated as compatible with lactation,” they wrote.

 “It is therefore crucial for providers to understand the risk of systemic absorption…in order to make informed decisions and safe recommendations to breastfeeding patients.”

CD Needle, AL Brinks, CA Kearney, et al. “Alopecia Treatments in Breastfeeding: Safety and Clinical Considerations,” International Journal of Dermatology (2025): 1–20, 

N Hunt and S McHale. “The Psychological Impact of Alopecia,” BMJ 331, no. 7522 (2005): 951–953, 

Articles

A recent review examines the safety of alopecia treatments for breastfeeding mothers, focusing on drug transfer to breast milk, infant serum levels, and potential neonatal adverse events. The review highlights the need for clinicians to make informed decisions about alopecia therapies during lactation, considering the limited research available. Various treatments, including minoxidil, JAK inhibitors, methotrexate, and others, are discussed in terms of their safety profiles and recommendations for breastfeeding mothers. The review emphasizes the importance of understanding systemic absorption risks to provide safe treatment options for lactating patients.

This review provides guidance to clinicians in choosing effective and safe alopecia therapies during breastfeeding periods.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Alopecia

Safety Considerations Highlighted for Alopecia Treatments During Breastfeeding

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Aimee Shu, MD | Image Credit: Stanford Medicine

Results from a 3-year phase 3 trial have indicated a sustained response to palopegteriparatide (TransCon PTH) therapy in adults with 

Announced by Ascendis Pharma on July 14, 2025, palopegteriparatide continued to provide durable responses in adults with hypoparathyroidism, regardless of whether it was post-surgical, autoimmune, genetic, or idiopathic. Biochemistries, kidney function, and quality of life were all significantly improved.

Hypoparathyroidism, a rare endocrine disease caused by insufficient levels of parathyroid hormone (PTH), the main regulator of phosphate and calcium balance. The disease acts directly on bones and the kidney and indirectly on the intestine. Several short-term and long-term complications, such as neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment, have been associated with hypoparathyroidism. Post-surgical hypothyroidism accounts for 70-80% of cases.

“We are pleased to report these latest data from our second clinical trial of TransCon PTH showing sustained efficacy and improvements across key health and quality of life measures, beginning at the earliest timepoints in the Phase 3 PaTHway trial and continuing through three years of treatment,” said Aimee Shu, MD, executive vixce president of Endocrine & Rare Disease Medical Science and chief medical officer at Ascendis Pharma. “These responses, including normalization of skeletal dynamics with significant and clinically meaningful improvements in kidney function, demonstrate the long-term benefits of this treatment option for the vast majority of adults with hypoparathyroidism, regardless of their disease etiology.”

The new data comes from Week 156 of the Phase 3 randomized, double-blind, placebo-controlled PaTHway trial, which consisted of a 26-week trial of 82 adults with chronic hypoparathyroidism followed by an open-label extension period through Week 182. The initial 26-week blinded period saw patients randomized in a 3:1 ratio to either palopegteriparatide or placebo. Investigators assessed their renal function by estimated glomerular filtration rate (eGFR). Safety assessments included 24-hour urine-calcium and treatment-emergent adverse events (TEAEs).

Hypoparathyroidism symptoms, as well as functioning and well-being, were measured via the Hypoparathyroidism Patient Experience Scale (HPES). The trial exhibited a high retention rate, with 73 of the initial 82 patients (89%) completing the full trial.

At the end of Week 156, a total of 64 participants (88%) had normal albumin-adjusted serum calcium levels. Additionally, 70 (96%) were no longer reliant on conventional therapy, which was defined as taking <600 mg/day of calcium and not taking active vitamin D. Improvements in eGFR were also sustained through Week 156: mean eGFR increased by 8.76 mL/min/1.73 m2 across all patients and by 13.98 mL/min/1.73 m2 in patients with baseline eGFR <60.

Continued improvements were reported from baseline through Week 156. Palopegteriparatide was well-tolerated and exhibited no new safety signals. TEAEs were mild to moderate, and no serious events or discontinuations from the trial were due to the study drug.

Palopegteriparatide has already been approved by the US Food and Drug Administration (FDA) to treat hypoparathyroidism in August of 2024, under the name YORVIPATH. Also developed by Ascendis Pharma, this treatment was a prodrug of parathyroid hormone (PTH[1-34]), administered once daily.

The approval came in response to a New Drug Application including data from the phase 2 PaTH Forward and the first portion of the phase 3 PaTHway trial. At the time, palopegteriparatide was the first and only treatment for hypoparathyroidism in adults.

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life. Ascendis Pharma. July 14, 2025. Accessed July 14, 2025. https://investors.ascendispharma.com/news-releases/news-release-details/new-3-year-phase-3-data-confirmed-sustained-response-transconr

FDA Approves YORVIPATH (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults. Ascendis Pharma. August 12, 2024. Accessed July 14, 2025. https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-yorvipathr-palopegteriparatide-first-and-only

A 3-year phase 3 trial demonstrated that palopegteriparatide (TransCon PTH) provides sustained benefits for adults with hypoparathyroidism, improving biochemistries, kidney function, and quality of life. The trial included 82 adults, with 89% completing the study. By Week 156, 88% achieved normal serum calcium levels, and 96% were off conventional therapy. The treatment was well-tolerated, with no serious adverse events. Palopegteriparatide, approved by the FDA in 2024 as YORVIPATH, remains the only treatment for adult hypoparathyroidism, offering significant long-term benefits across various etiologies.

Already approved by the FDA based on data from the first half of the PaTHway trial, 3-year extended results have indicated lasting efficacy.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Thyroid Disorders

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Palopegteriparatide Provides Sustained Response in Adults with Hypoparathyroidism

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Liver Lineup: Progress, Policy, and Barriers in Hepatitis C Elimination

Liver Lineup: Updates & Unfiltered Insights

, hosts Kimberly Brown, MD, a professor of Medicine at Michigan State University and Wayne State University, associate medical director of the Henry Ford Hospital Transplant Institute, and medical director of Transplant Outreach Services at Henry Ford Hospital, and Nancy Reau, MD, a professor of internal medicine, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation, and the section chief of hepatology at Rush University Medical Center, discuss the progress and persistent challenges in eliminating 

With highly effective, short-course oral therapies now available, Brown and Reau emphasize that curing HCV is more achievable than ever. The discussion explores the major policy, clinical, and structural milestones enabling this effort—and the critical gaps in diagnosis, treatment access, and health policy that still impede progress.

Reau opens by emphasizing the revolutionary nature of curative HCV therapies, which not only improve individual health outcomes but also reduce transmission, presenting a rare opportunity for public health impact on a global scale. She and Brown discuss how national and international efforts, including World Health Organization goals and US legislation, have aligned to prioritize viral hepatitis elimination.

Specifically, the hosts discuss the role of the US Preventive Services Task Force and the Affordable Care Act in establishing HCV screening as a covered preventive service. Outlining the evolution from birth cohort screening to universal screening for adults 18 and over, Reau and Brown discuss a recent legal challenge to the Affordable Care Act’s preventive service mandate that threatened access to HCV screening. The Supreme Court’s 6–3 decision to uphold this provision was, in their view, a critical win for public health and HCV elimination.

Despite these advances, both experts acknowledge major challenges remain in the HCV care cascade. Many patients are lost between screening and cure, often due to provider restrictions, system fragmentation, and lack of prioritization. They emphasize the need for government-backed elimination efforts, drawing lessons from successful national programs in countries like Egypt and Georgia.

The conversation also underscores the role of grassroots advocacy, emphasizing the critical role clinicians and patients alike can play in supporting federal hepatitis elimination legislation. Most importantly, they encourage patients to share their stories with legislators—a strategy proven effective in other public health movements, including HIV.

Reau additionally calls upon listeners to write to their local senators to support bipartisan legislation from senators Bill Cassidy (R-LA) and Chris Van Hollen (D-MD) to eliminate hepatitis C using the following link: 

Ask Senators to Cosponsor the Cure Hepatitis C Act

Editors’ note: Relevant Disclosures for 

 include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for 

 include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

Podcasts

Hosts Kimberly Brown and Nancy Reau discuss policy, clinical, and structural milestones enabling HCV elimination efforts and critical gaps impeding progress.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Jonathan Meyer, MD, is a clinical professor of Psychiatry at UC San Diego and nationally recognized psychopharmacology educator.

At the 2025 Southern California Psychiatry Conference at Huntington Beach, CA, from July 11 – 12, Jonathan Meyer, MD, presented on muscarinics and 

, a brand under MJH Life Sciences, Meyer, a voluntary clinical professor at the University of California, San Diego, discussed what’s new in tardive dyskinesia, when to switch medications, and how the only effective treatment for this condition is VMAT2 inhibitors.

In this Q&A, Meyer emphasized the importance of making sure you diagnose tardive dyskinesia correctly, not mixing up tardive dyskinesia with Parkinsonism. Medications for Parkinsonism worsen tardive dyskinesia symptoms, and vice versa. Only 2 FDA-approved medications for tardive dyskinesia sit on the market—tetrabenazine and valbenazine—both vesicular monoamine transporter 2 (VMAT2) inhibitors.

 The big thing that's new is not the medications. We've had two FDA-approved treatments in 2017, but in the early days when they're just approved, I think the focus was more on detecting tardive dyskinesia. We've come to appreciate that it's not just the movements, it's the functional impact, the impact on the person's well-being, the impact on psychosocial functioning.

A big aspect of what I'll be covering today is really how to use some of these newer instruments that have been developed to help you figure out for your patients with TD, how it interferes with what they do on a day-to-day basis, not just physically, but psychologically and socially.

If you have a patient and you're giving the medication for TD, and you don't see that they're improving, what are some of the things that clinicians should be thinking about?

 Well, for one thing, you want to make sure that you have the right diagnosis. There are sometimes movements [that] can happen to people on psychotropic [medications], which may lead the clinician to think they have tardive dyskinesia.

A classic example is a form of Parkinsonism, in which the person has jaw tremors, because it's in this area, we often would assume it's tardive dyskinesia, and most of the time, you're right…if they've been exposed to a D2 blocker, but in this case, it's actually a form of Parkinsonism. The medicines [that] make Parkinsonism better tend to make TD worse. Conversely, for people with Parkinsonism, the medicines for TD tend to make those symptoms worse.

If you assume, though, that you have the correct diagnosis, the most important thing is making sure the person's taking the medication and that you've maximized the dose. If there is no response whatsoever on the maximal dose of one medication, there's really no harm in trying the other one. We only have 2 options right now, which are FDA-approved, but there are a subset of people with TD who don't get adequate improvement with either of the 2 FDA-licensed medications. Those are the types of people who you may refer to a neurologist for further evaluation and treatment.

Between the two, how should a clinician decide which one they're going to start trying? Is there a rhyme or reason to it?

 There really often isn't. One of them has a bit more of a titration schedule, which is tetrabenazine. Does that always cause a problem? Not necessarily. There are actually some people who prefer a lower initiation schedule.

Valbenazine is easier to initiate. 40 milligrams is the starting dose, and it's actually a very effective dose. I say to clinicians: you need to know how to use both, simply because insurance, more than anything, may dictate what you have access to. They are both effective.

We don't have any head-to-head data. There's inferential data from imaging studies that maybe you might get more VMAT2 occupancy, perhaps at the maximal dose of valbenazine versus the maximal dose of tetrabenazine. I can't promise there's always a clinical correlate for that, but it emphasizes a point of [knowing] how to use both. Maybe somebody will respond better, or perhaps a differential tolerability to one or the other.

Any closing thoughts that you want to share with clinicians?

 The only effective treatments for tardive dyskinesia are the VMAT2 inhibitors. In the old days, people used to throw medicines like benztropine against all movement disorders with the D2 blockade. We now know that they're not effective for TD, and in fact, they tend to make it worse.

The only thing I'll say about that is, if you have people on anticholinergics at some point in their treatment, if they have TD, you want to slowly taper them off to allow the VMAT2 inhibitor to give you your maximum benefit for their movements, most importantly, to improve their quality of life related to their tardive dyskinesia.

Jonathan Meyer, MD, presented insights on tardive dyskinesia (TD) at the 2025 Southern California Psychiatry Conference. He emphasized the importance of accurate diagnosis, distinguishing TD from Parkinsonism, as treatments for one can exacerbate the other. The only FDA-approved treatments for TD are VMAT2 inhibitors, tetrabenazine and valbenazine. Meyer highlighted the need to assess the functional impact of TD on patients' lives and suggested trying both medications if one proves ineffective. He advised tapering off anticholinergics to maximize the benefits of VMAT2 inhibitors.

Discover the latest insights on tardive dyskinesia treatment, diagnosis, and the role of VMAT2 inhibitors in enhancing patient well-being.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

What’s New in Tardive Dyskinesia, With Jonathan Meyer, MD

Auchus discusses his recent presentation on the CATALYST trial, investigating the characteristics of patients with difficult-to-treat T2D because of hypercortisolism.

Type 2 Diabetes

Hypercortisolism in Patients with Treatment-Resistant Type 2 Diabetes, with Richard Auchus, MD, PhD

A panelist discusses how indolent systemic mastocytosis presents with chronic, mast cell–mediated symptoms that significantly reduce quality of life, often persist despite treatment, and may lead to serious complications like anaphylaxis and osteoporosis.

Video Series

Understanding Indolent Systemic Mastocytosis (ISM): Symptoms and Impact

The previously approved technology has already accomplished over 10,000 procedures for patients with various heart diseases, primarily including atrial fibrillation.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

FDA News

FDA Approves Updated VARIPULSE Platform Irrigation Flow Rate for Heart Disease

Post-Doctoral Fellow at the Emory Global Diabetes Research Center

Lifestyle intervention yielded greater maintained weight loss 12 months after discontinuing semaglutide than without.

Concurrent Lifestyle Intervention Enhances Semaglutide Weight Loss, with Qiaochu Xue, PhD, MPH

BaxHTN trial results showed baxdrostat led to a significant reduction of systolic blood pressure compared to placebo, with a favorable safety profile.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Baxdrostat Meets Efficacy Endpoint in Phase 3 Trial for Resistant Hypertension

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Treatment with baxdrostat resolved or reduced the severity of hypertension, excessive aldosterone production, and hypokalemia in the phase 2a SPARK trial.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Phase 2a Baxdrostat Data Show Promise for Primary Aldosteronism

This systematic review evaluated current research on dual biologic treatments in patients living with inflammatory skin conditions.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Review Highlights Benefits, Drawbacks of Dual Biologic Therapy in Dermatology

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Finerenone gains FDA approval for heart failure treatment, offering new hope for patients with reduced ejection fraction and improving care options.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Chronic Kidney Disease

FDA Approves Finerenone (Kerendia) for Heart Failure with Ejection Fraction of 40% or More

Evan Dellon, MD, MPH, is a professor in the division of gastroenterology and hepatology and director of the Center for Esophageal Diseases and Swallowing at UNC School of Medicine.

Panelists discuss how first-line eosinophilic esophagitis (EoE) treatment involves shared decision-making between proton pump inhibitors, topical swallowed steroids, or food elimination diets, with therapy selection based on patient preferences, lifestyle factors, developmental stage in children, and the understanding that treatment approaches can evolve over time as circumstances change.

Choosing a First- Line Therapy for EoE

A panelist discusses the potential of remibrutinib as an effective oral alternative to omalizumab for chronic spontaneous urticaria (CSU), noting its rapid onset, promising trial results, and anticipated use in patients who prefer oral therapy or have not responded to biologics.

Insights

 Insights page is a resource for professional video interviews with leading clinical experts and investigators across all specialties of medicine.

Latest News

Examining APP-Led Endobronchial Valve Therapy for COPD, with Haley Hoy, PhD, CRNP

Safety Considerations Highlighted for Alopecia Treatments During Breastfeeding

Palopegteriparatide Provides Sustained Response in Adults with Hypoparathyroidism

Liver Lineup: Progress, Policy, and Barriers in Hepatitis C Elimination

What’s New in Tardive Dyskinesia, With Jonathan Meyer, MD